SURPASS Trial Program — Tirzepatide for T2 Diabetes

Detail

SURPASS-2 (Frías JP, NEJM 2021, n=1,879, PMID 34170647) compared tirzepatide head-to-head against semaglutide. Tirzepatide demonstrated superior glycemic control AND approximately 47% greater weight loss at all doses. The SURPASS program continues to evaluate cardiovascular outcomes via SURPASS-CVOT.

Sources

This page references peer-reviewed publications listed on PubMed and FDA prescribing information labels. Methodology for source selection is documented on the Methodology page.